First study of ARD001 in healthy people and those with hemophilia A
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This study tests a new medicine, ARD001, for the first time in humans. It aims to see if the drug is safe and how the body handles it, and it is also being studied in people with hemophilia A to find a safe dose for future trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are in overall good health with no major medical conditions.
- You do not have a history of severe allergic reactions to drugs or foods.
- You do not have a current infection or fever.
- You do not have significant heart, liver, kidney, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
This Phase 1/2 study tests a one-time gene therapy (ASC618) to help the body make clotting factor for people with hemophilia A. It may reduce bleeding and the need for factor infusions, but you must meet several safety and eligibility checks.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.